Hangzhou Alltest Biotech Co. Ltd. A (688606) — Capital Reinvestment Ratio

Latest as of September 2025: 0.69x

Hangzhou Alltest Biotech Co. Ltd. A (688606) has a Capital Reinvestment Ratio of 0.69x as of September 2025, meaning it reinvests 1% of its operating cash flow (CN¥55.21 Million) in capital expenditures (CN¥38.02 Million). Check Hangzhou Alltest Biotech Co. Ltd. A tangible equity quality to evaluate the tangible quality of the company's equity base.

Capital Reinvestment Ratio

0.69x
Capex / Operating Cash Flow

Operating Cash Flow

CN¥55.21 Million
CNY

Capital Expenditures

CN¥38.02 Million
CNY

Data as of

Sep 2025
Most recent filing

Hangzhou Alltest Biotech Co. Ltd. A Capital Reinvestment Ratio (2016–2025)

This chart tracks Hangzhou Alltest Biotech Co. Ltd. A's Capital Reinvestment Ratio across 10 annual periods. For the full cash flow conversion analysis, see 688606 cash flow conversion.

Annual Capital Reinvestment Ratio for Hangzhou Alltest Biotech Co. Ltd. A (2016–2025)

Year-by-year Capital Reinvestment Ratio for Hangzhou Alltest Biotech Co. Ltd. A from 2016 to 2025. See 688606 cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.

Year Reinvestment Ratio Operating CF (CNY) Capital Expenditures YoY Change
2025 1.06x CN¥206.59 Million CN¥219.10 Million ▲ +58.4%
2024 0.67x CN¥329.52 Million CN¥220.65 Million ▼ -96.9%
2023 21.54x CN¥24.76 Million CN¥533.49 Million ▲ +10747.3%
2022 0.20x CN¥1.36 Billion CN¥270.24 Million ▲ +30.9%
2021 0.15x CN¥923.87 Million CN¥140.12 Million ▲ +154.5%
2020 0.06x CN¥622.72 Million CN¥37.11 Million ▼ -63.8%
2019 0.16x CN¥91.53 Million CN¥15.09 Million ▼ -91.2%
2018 1.86x CN¥18.60 Million CN¥34.66 Million ▼ -28.5%
2017 2.61x CN¥19.99 Million CN¥52.12 Million ▲ +740.1%
2016 0.31x CN¥6.72 Million CN¥2.08 Million
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow